Ambrosia Biosciences, a Boulder-based drug discovery company, has raised $100 million in an oversubscribed Series B funding round co-led by Blue Owl Healthcare Opportunities, Redmile Group and Deep Track Capital. The company develops orally bioavailable small molecule therapies targeting Class B GPCRs like GLP-1R, GIPR and Amylin for obesity and cardiometabolic disorders. The capital will advance its lead oral GLP-1R agonist through IND-enabling studies to Phase 1 clinical trials and progress other pipeline programs.
Oral GLP-1 Race Accelerates
The funding arrives amid surging interest in oral small molecule alternatives to injectable GLP-1 therapies. Structure Therapeutics reported positive Phase 2 data for its oral GLP-1 agonist aleniglipron just two weeks prior, achieving 16.3% placebo-adjusted weight loss and planning Phase 3 trials in H2 2026 per company release. Eli Lilly's orforglipron demonstrated superior efficacy to oral semaglutide in Phase 3, with PDUFA in April 2026. Ambrosia's integrated cryo-EM and AI-driven platform positions it to compete in this validated space.
Injectable Limitations Drive Demand
Over 1 billion people worldwide suffer from obesity, fueling demand for more accessible treatments beyond weekly injections. Current GLP-1 peptides like Ozempic succeed commercially but face adherence challenges due to administration. Oral small molecules promise once-daily dosing with potential for lower doses and better combinability, addressing key patient pain points.
Cryo-EM Unlocks GPCR Targets
Ambrosia leverages cryo-EM structural biology and AI-powered design in its 24,000 sq ft integrated labs on the former Array BioPharma campus. Its lead GLP-1R agonist offers potential 24-hour coverage and combo potential, while discovery programs target GIPR antagonist for enhanced efficacy and amylin agonist for monotherapy. This approach differentiates from competitors like Septerna, which raised $103M Series A and partners with Novo Nordisk on early-stage incretins.
As Ambrosia CSO John Mayer noted in a preclinical presentation:
"Discovery and Nonclinical Profile of AMB-234, a Novel, Orally Bioavailable GLP-1 Receptor Agonist."
Growth Capital Backs Clinic Push
Co-leads Blue Owl (part of $300B+ AUM firm) and Redmile (with IPO exits like Revolution Medicines) signal growth-stage conviction in Ambrosia's platform. Existing investors BVF Partners and Boulder Ventures participated, alongside new backers Janus Henderson Investors and Samsara BioCapital. Prior Merck strategic investment in the $25M Series A adds pharma validation.
Anti-Obesity Market Explodes
The anti-obesity drugs market stands at $22.5 billion in 2026, projected to reach $196 billion by 2036 at 24.2% CAGR per market analysis. Trends favor oral formulations, with Novo Nordisk's oral Wegovy approved in December 2025 and Lilly's pending. Viking Therapeutics, with over $100M pre-IPO, advances a dual GLP-1/GIP oral agonist in Phase 2.
Array Veterans Lead Charge
Chairman Kyle Lefkoff founded Array BioPharma, acquired by Pfizer for $11.8 billion, and recruited ex-Array/Pfizer Boulder team with track record of 30 INDs, 25 NMEs and 7 FDA approvals. CEO Nick Traggis brings two biotech exits, including LightDeck Diagnostics to Heska. Advisors include GLP-1 pioneer Richard DiMarchi.
Phase 1 Trials Advance Pipeline
Proceeds fund Phase 1 initiation for the oral GLP-1R agonist and advancement of GIPR antagonist and amylin programs. Recent preclinical data on lead candidate AMB-234 was presented at ObesityWeek 2025, with Colorado BioScience Rising Star Award underscoring momentum.